ES2009216A6 - Metodo de preparar un derivado de interleucina-lalfa. - Google Patents

Metodo de preparar un derivado de interleucina-lalfa.

Info

Publication number
ES2009216A6
ES2009216A6 ES8701022A ES8701022A ES2009216A6 ES 2009216 A6 ES2009216 A6 ES 2009216A6 ES 8701022 A ES8701022 A ES 8701022A ES 8701022 A ES8701022 A ES 8701022A ES 2009216 A6 ES2009216 A6 ES 2009216A6
Authority
ES
Spain
Prior art keywords
alpha
1alpha
drugs
derivatives
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8701022A
Other languages
English (en)
Inventor
Satoru Nakai
Mayumi Kaneta
Yoshikazu Kikumoto
Yeong-Man Hong
Kazuyoshi Kawai
Setsuko Takegata
Kiyoshi Ishii
Yasuo Yanagihara
Yoshikatsu Hirai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of ES2009216A6 publication Critical patent/ES2009216A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
    • F16L5/00—Devices for use where pipes, cables or protective tubing pass through walls or partitions
    • F16L5/02—Sealing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

METODO DE PREPARAR UN DERIVADO DE INTERLUUCINMA-1ALFA (IL-1ALFA), QUE TIENE UNA SECUENCIA MODIFICADA DE AMINOACIDOS. EL METODO CONSISTE EN INCUBAR UN CELULA TRANSFORMANTE QUE TIENE UN VECTOR DE EXPRESION (TAL COMO UN VIRUS O UN ORGANULO CELULAR ADECUADO) QUE INCLUYE UN GEN QUE CODIFICA PARA EL DERIVADO DE IL-1ALFA PARA PRODUCIR EL DERIVADO Y RECOPGER EL DERIVADO ASI PRODUCIDO, SIENDO DICHO DERIVADO DE IL-1ALFA UN POLIPEPTIDO QUE TIENE UNA SECUENCIA MODIFICADA DE AMINOACIDOS QUE CUMPLE DETERMINADOS REQUISITOS. ALGUNOS DE LOS PRODUCTOS OBTENIDOS TIENEN APLICACIONES FARMACEUTICAS.
ES8701022A 1986-03-14 1987-03-13 Metodo de preparar un derivado de interleucina-lalfa. Expired ES2009216A6 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP5788586 1986-03-14
JP12975986 1986-06-03
JP14839386 1986-06-25
JP16025086 1986-07-08
JP20032386 1986-08-27

Publications (1)

Publication Number Publication Date
ES2009216A6 true ES2009216A6 (es) 1989-09-16

Family

ID=27523408

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8701022A Expired ES2009216A6 (es) 1986-03-14 1987-03-13 Metodo de preparar un derivado de interleucina-lalfa.

Country Status (7)

Country Link
US (5) US5008374A (es)
EP (2) EP0578278A1 (es)
JP (1) JP2572220B2 (es)
KR (1) KR950000886B1 (es)
DE (1) DE3750432T2 (es)
DK (2) DK171647B1 (es)
ES (1) ES2009216A6 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831022A (en) * 1986-02-18 1998-11-03 Hoffmann-La Roche Inc. Purification of recombinant human IL-1α
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
US5290917A (en) * 1988-02-03 1994-03-01 Dainippon Pharmaceutical Co., Ltd. Modified polypeptides of IL-1α
JP2698976B2 (ja) * 1988-02-03 1998-01-19 大日本製薬株式会社 新規ポリペプチド及びそれをコードするｄｎａ
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
EP0644203A1 (en) * 1988-07-29 1995-03-22 Otsuka Pharmaceutical Co., Ltd. IL-1alpha derivatives and medicament for treating thrombocytopenia
US5649904A (en) * 1988-10-07 1997-07-22 Sandoz Ltd. Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both
EP0460052B1 (en) * 1989-02-27 1998-04-15 New England Medical Center Il-1 biological activity inhibitors
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
EP0495131B1 (en) * 1990-08-10 1997-05-14 Otsuka Pharmaceutical Co., Ltd. Agent for preventing and treating hepatitis
US5723117A (en) * 1990-08-10 1998-03-03 Otsuka Pharmaceutical Co., Ltd. Use of interleukin-1 (IL-1) to inhibit development of hepatitis
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤
JPH06196070A (ja) * 1992-12-24 1994-07-15 Nec Corp 電磁継電器
US5866134A (en) * 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
US7176179B1 (en) 1997-05-30 2007-02-13 The Regents Of The University Of California Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
US6191269B1 (en) 1997-05-30 2001-02-20 The Regents Of The University Of California Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
WO1999037321A1 (fr) * 1998-01-22 1999-07-29 Gosudarstvenny Nauchno-Issledovatelsky Institut Osobo Chistykh Biopreparatov (Gosnii Ochb) Preparation immuno-modulatrice a base d'interleukine 1 et procede de preparation
US20030154504A1 (en) * 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
AU2002248192A1 (en) * 2000-12-15 2002-08-12 Stratagene Room temperature stable competent cells
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
AU2002348297A1 (en) * 2001-11-20 2003-06-10 Proteex, Inc. Proteonomic methods for diagnosis and monitoring of breast cancer
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568640A (en) * 1981-05-11 1986-02-04 Harvey Rubin Method of inserting amino acid analogs into proteins
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4512974A (en) * 1982-12-08 1985-04-23 Moldawer Lyle L Treatment of protein malnourished surgical patients
US4542017A (en) * 1982-12-09 1985-09-17 Moldawer Lyle L Treatment of protein malnourished bacterially infected humans with LEM
FR2550802B1 (fr) * 1983-08-17 1986-04-11 Inst Nat Sante Rech Med Procede de production d'interleukine 1 humaine et medicaments correspondants
JPS60149386A (ja) * 1984-01-17 1985-08-06 Dainippon Pharmaceut Co Ltd インタ−ロイキン１をコ−ドする伝令リボ核酸及びその調製法
CA1341401C (en) * 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
EP0155433A1 (en) * 1984-03-23 1985-09-25 Adriano Fontana Immunosuppressant factor
DE3588241T2 (de) * 1984-05-18 2002-12-05 Massachusetts Institute Of Technology, Cambridge Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
CA1340978C (en) * 1984-06-19 2000-05-02 Douglas P. Cerretti Purification, cloning and characterization of the gene for interleukin 1
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
DE3587605T2 (de) * 1984-12-25 1994-03-17 Dainippon Pharmaceutical Co Interleukin-1 und dessen Derivat.
AU577856B2 (en) * 1985-01-17 1988-10-06 Immunex Corporation Cloning and characterization of the human interleukin 1 gene
EP0200986B2 (en) * 1985-04-25 1998-03-11 F. Hoffmann-La Roche Ag Recombinant human interleukin-1
IT1188550B (it) * 1986-02-07 1988-01-14 Sclavo Spa Peptide sintetico ad attivita' interleukina 1 umana
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
US5017692A (en) * 1986-09-04 1991-05-21 Schering Corporation Truncated human interleukin-a alpha
US5047505A (en) * 1987-01-27 1991-09-10 Du Pont Merck Pharmaceutical Company High level expression in E. coli of soluble mature HIL-1beta and derivatives with altered biological activity
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
US5211946A (en) * 1991-09-13 1993-05-18 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides

Also Published As

Publication number Publication date
US5342615A (en) 1994-08-30
HK1003115A1 (en) 1998-10-09
EP0578278A1 (en) 1994-01-12
US5008374A (en) 1991-04-16
EP0237073A3 (en) 1989-11-15
DK172339B1 (da) 1998-04-06
EP0237073B1 (en) 1994-08-31
DK127787D0 (da) 1987-03-12
DK51493A (da) 1993-05-05
US5702698A (en) 1997-12-30
DE3750432T2 (de) 1995-04-20
US5371204A (en) 1994-12-06
US5543140A (en) 1996-08-06
KR950000886B1 (ko) 1995-02-03
JPS63164899A (ja) 1988-07-08
EP0237073A2 (en) 1987-09-16
DK171647B1 (da) 1997-03-03
DE3750432D1 (de) 1994-10-06
JP2572220B2 (ja) 1997-01-16
KR870009023A (ko) 1987-10-22
DK127787A (da) 1987-09-15
DK51493D0 (da) 1993-05-05

Similar Documents

Publication Publication Date Title
ES2009216A6 (es) Metodo de preparar un derivado de interleucina-lalfa.
ES2009215A6 (es) Procedimiento de preparar un derivado de interleucina-1beta.
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
MY100721A (en) Therapeutic agent.
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
ATE66614T1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
MY100998A (en) Pharmaceutical formulations
ZA87793B (en) Formulations suitable for the stabilisation of alpha-interferon
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
CS357991A3 (en) Benzimidazole derivatives, process of their preparation and pharmaceutical compositions comprising said derivatives
IT1183181B (it) Derivati del 3-metil-imidazo(4,5-c)pirazolo con attivita' terapeutica e procedimento per la loropreparazione
NO863398L (no) Smaksmaskerende preparater.
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
FI891712A7 (fi) Terapeuttisesti vaikuttavia syklometyleeni-1,2-bikarboksyylihappojen amiineja, menetelmiä niiden valmistamiseksi sekä niitä sisältäviä farmaseuttisia koostumuksia
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
ATE81775T1 (de) Pharmazeutische zusammensetzungen.
ES8703742A1 (es) Procedimiento para preparar un agente acuoso esteril de ac- cion retardada y prolongada,de un peptido o de una proteina
ATE84221T1 (de) Arzneimittel mit methylcellulose.
EP0218953A3 (en) Derivatives of 19,20-bis-nor-prostanoic acid with antiulcer and anorectic activity, process for their preparation and pharmaceutical compositions thereof
DE3761561D1 (de) N,n-bis-(4-fluorophenyl)carbamoylacetohydroxamsaeure und diese enthaltende pharmazeutische zusammensetzungen.
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
FI896003A7 (fi) Prourokinaasin johdannaiset, joilla on alhainen molekyylipaino, ja nii tä sisältävät farmaseuttiset koostumukset
KR870010080A (ko) 면역촉진 활성을 갖는 트리펩티드
ATE102934T1 (de) Fluorierte flavon-essigsaeure.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20041102